Biotech New Lows: Direxion Daily Real Estate (NYSEARCA:DRN) , Amicus Therapeutics (NASDAQ:FOLD) , ArQule (NASDAQ:ARQL), Uniqure (NASDAQ:QURE)

Direxion Daily Real Estate Bull 3X (ETF) (NYSEARCA:DRN) looks to achieve high returns, to the tune of 300%, on the Russell 1000 Financial Services Index. This ETF is on daily investment results and is one of the subsets of the Russell 100 Index. This Index typically noted the performance of securities of financial service providers, of the large cap variety – belonging to the United States Equity Market. Direxion Daily Real Estate Bull 3X (ETF)(NYSEARCA:DRN) shares after opening at $52.33 moved to $52.99 on last trade day and at the end of the day closed at $52.82. Company price to sales ratio in past twelve months was calculated as 11.42 and price to cash ratio as 6.62. Direxion Daily Real Estate Bull 3X (ETF)(NYSEARCA:DRN) showed a positive weekly performance of 2.36%.

Amicus Therapeutics, Inc, Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a big move last session, as the company’s shares fell by 8% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $2.04 to $2.32 in the past one-month time frame. Amicus Therapeutics, Inc.(NASDAQ:FOLD) shares fell -1.09% in last trading session and ended the day on $1.82. FOLD return on equity ratio is recorded as -144.30% and its return on assets is -64.10%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) yearly performance is -35.69%.

A number of analysts have recently weighed in on ArQule, Inc. (NASDAQ:ARQL) shares. Analysts at Zacks downgraded shares of ArQule from an “outperform” rating to a “neutral” rating in a research note on Wednesday, January 29th. They now have a $2.80 price target on the stock. Five research analysts have rated the stock with a hold rating, ArQule presently has a consensus rating of “Hold” and an average price target of $3.26.ArQule, Inc.(NASDAQ:ARQL) shares moved down -1.16% in last trading session and was closed at $1.71, while trading in range of $ 1.69 – 1.77. ArQule, Inc. (NASDAQ:ARQL) year to date (YTD) performance is -20.47%.

uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr. Goossens has a 15-year track record of management and leadership in technology-based companies, including the biopharmaceutical industry, with particular experience in the oversight of operations and site management. In addition, uniQure welcomed Deya Corzo, M.D., in the position of Vice President, Medical Affairs for the United States as of April 1, 2014.Uniqure NV (NASDAQ:QURE) weekly performance is -37.21%. On last trading day company shares ended up $9.10. Uniqure NV (NASDAQ:QURE) distance from 50-day simple moving average (SMA50) is -43.31%. Analysts mean target price for the company is $28.00.